High rates of pathological complete response were reported with neoadjuvant datopotamab deruxtecan plus durvalumab in patients with specific subtypes of breast cancer and at high risk of recurrence

New positive findings from research in advanced or metastatic breast cancer support the use of these agents in wider patient populations

First recommendations are released from the ESMO/SIOG Cancer in the Elderly Working Group 

Efficacy and safety of the first-line novel combination were assessed in patients with untreated PD-L1 positive locally advanced or metastatic tumours

A synergic effect of olaparib, durvalumab and fulvestrant was observed across different mutated subgroups, with higher benefits in BRCA 1 and 2 carriers

Studies provide evidence of potential efficacy for a novel CDK4-selective inhibitor and long-lasting benefits for a pan-AKT inhibitor

Two studies provide new insights on the effects of vaginal oestrogen therapy and physical exercise to tackle sexual impairment

In the TROPION-Breast01 trial, adverse events of special interest were generally low grade, easily managed and did not compromise scheduled treatment